MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.36
-0.65
-4.33%
After Hours: 14.69 +0.33 +2.30% 16:24 05/24 EDT
OPEN
14.70
PREV CLOSE
15.01
HIGH
14.73
LOW
14.10
VOLUME
1.49M
TURNOVER
0
52 WEEK HIGH
28.00
52 WEEK LOW
11.91
MARKET CAP
2.26B
P/E (TTM)
-6.2467
1D
5D
1M
3M
1Y
5Y
4 Analysts Have This to Say About Iovance Biotherapeutics
Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings:
Benzinga · 4h ago
--Goldman Sachs Adjusts Price Target for Iovance Biotherapeutics to $64 From $79, Keeps Buy Rating
MT Newswires · 10h ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on May 19, 2022 (the “Date of Grant”), the Comp...
GlobeNewswire · 3d ago
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Zacks · 05/06 14:45
BRIEF-Iovance Biotherapeutics Reports First Quarter 2022 Financial Results
reuters.com · 05/05 22:19
Iovance Biotherapeutics Q1 EPS $(0.58) Beats $(0.64) Estimate
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.64) by 9.38 percent. This is a 13.73 percent decrease over losses of $(0.51) per share
Benzinga · 05/05 20:59
Iovance Biotherapeutics GAAP EPS of -$0.58 beats by $0.06
Iovance Biotherapeutics press release (NASDAQ:IOVA): Q1 GAAP EPS of -$0.58 beats by $0.06. Cash position of $516.0 million at March 31, 2022 is expected to be sufficient into 2024.
Seekingalpha · 05/05 20:11
Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting
SAN CARLOS, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that translational data for lifileucel in patients...
GlobeNewswire · 04/27 20:01
More
No Data
Learn about the latest financial forecast of IOVA. Analyze the recent business situations of Iovance Biotherp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
57.14%Buy
14.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IOVA stock price target is 35.08 with a high estimate of 79.00 and a low estimate of 20.00.
High79.00
Average35.08
Low20.00
Current 14.36
EPS
Actual
Estimate
-0.51-0.38-0.26-0.13
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 345
Institutional Holdings: 171.07M
% Owned: 108.85%
Shares Outstanding: 157.17M
TypeInstitutionsShares
Increased
104
18.15M
New
42
4.00M
Decreased
64
15.62M
Sold Out
38
6.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Director
Iain Dukes
President/Chief Executive Officer/General Counsel/Secretary
Frederick Vogt
Chief Operating Officer
Igor Bilinsky
Vice President - Finance
Michael Swartzburg
Other
Friedrich Graf Finckenstein
Director
Athena Countouriotis
Independent Director
Ryan Maynard
Independent Director
Merrill Mcpeak
Independent Director
Wayne Rothbaum
Independent Director
Michael Weiser
No Data
No Data
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. The Company’s lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, the Company is investigating the effectiveness and safety of TIL therapy and peripheral blood lymphocyte (PBL) therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer (NSCLC), and chronic lymphocytic leukemia (CLL).

Webull offers kinds of Iovance Biotherapeutics Inc stock information, including NASDAQ:IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.